Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, H…
Drug Manufacturers - General
US, Indianapolis [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 38.17 | 220.77 | 159.79 | |
| Graham Fair Price | 16.33 | 28.23 | 24.27 | |
| PEG | 57609.22 | 9.80 | -0.02 | |
| Price/Book | 4.08 | 53.47 | 51.38 | |
| Price/Cash Flow | 1252.32 | 3812.48 | -281.92 | |
| Prices/Earnings | 20.86 | 76.36 | 63.18 | |
| Price/Sales | 32.06 | 78.14 | 59.17 | |
| Price/FCF | 1252.32 | 3812.48 | -281.92 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.29 | 0.83 | 0.82 | |
| Operating Margin | -9.22 | 0.30 | 0.33 | |
| ROA | 2.53 | 0.04 | 0.03 | |
| ROE | 0.20 | 0.18 | -13.88 | |
| ROIC | 0.07 | 0.06 | -20.45 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.04 | 0.25 | -84.41 | |
| Dividends QOQ | -0.05 | 0.21 | 316.94 | |
| EBIT QOQ | 5.83 | -0.15 | -97.45 | |
| EPS QOQ | 37.21 | 0.08 | -99.79 | |
| FCF QOQ | -0.08 | 1.09 | 1207.04 | |
| Revenue QOQ | -0.02 | -0.06 | -309.43 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 313.17 | 357.90 | 14.28 | |
| Days Sales Outstanding (DSO) | 109.08 | 102.78 | -5.77 | |
| Inventory Turnover | 0.29 | 0.25 | -12.50 | |
| Debt/Capitalization | 0.70 | 0.67 | -4.15 | |
| Quick Ratio | 0.52 | 0.68 | 29.63 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 11.35 | 14.22 | 25.36 | |
| Cash | 3.08 | 2.87 | -6.90 | |
| Capex | -1.74 | -1.09 | 37.04 | |
| Free Cash Flow | -2.07 | 0.20 | -90.35 | |
| Revenue | 9.85 | 9.73 | -1.20 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Weak